Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Botanix Pharmaceuticals Limited ( (AU:BOT) ) has shared an update.
Botanix Pharmaceuticals announced that its CEO, Dr. Howie McKibbon, will present at the Canaccord Genuity 45th Annual Growth Conference in Boston, which is a significant event attracting institutional fund managers and growth companies from the healthcare and life sciences sectors. This participation underscores Botanix’s strategic positioning in the industry and highlights its commitment to engaging with key stakeholders and investors, potentially enhancing its market presence and investor relations.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
More about Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Limited is a dermatology company based in Philadelphia and Phoenix, US. It focuses on developing treatments for dermatological conditions and has received FDA approval for its lead product, Sofdra, which treats primary axillary hyperhidrosis. Sofdra is notable for being the first and only new chemical entity approved by the FDA for this condition, providing a novel solution for patients with limited treatment options.
Average Trading Volume: 16,134,237
Technical Sentiment Signal: Sell
Current Market Cap: A$294.2M
For an in-depth examination of BOT stock, go to TipRanks’ Overview page.